Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Chirfi Guindo will lead Human Health Marketing as chief marketing officer for Merck Human Health, and will join Merck’s Executive Team, effective July 1, 2022. Guindo will report directly to Robert M. Davis, chief executive officer and president, Merck. As previously announced, Jannie Oosthuizen leads Merck Human Health U.S., and Joe Romanelli will lead Merck Human Health International effective Aug. 1, both also reporting to Davis. Deepak Khanna, interim leader of Human Health International, will retire at the end of this year.
“Chirfi is a purpose-driven leader, dedicated to saving and improving lives around the world. He has deep experience and a proven track record in strategy, marketing and commercialization across primary care, specialty care and rare diseases, in both developed and developing markets,” said Mr. Davis. “I am confident that our Human Health leaders, along with our entire Executive Team, will build on the strong momentum of our business as we deliver value to all our stakeholders, continue to address some of the most pressing medical challenges and make a positive and lasting impact on global health.”
As chief marketing officer for Human Health, Guindo will be responsible for leading the development and implementation of the company’s long-term strategy for the Human Health portfolio spanning oncology, vaccines, pharmaceutical and pipeline products.
Since 2017, Guindo has been executive vice president and head of global product strategy and commercialization at Biogen and served on Biogen’s executive leadership team. In this role, Guindo led global strategy, marketing and commercialization for Biogen’s neurology business. He also led the late-stage Product Development and Commercialization Teams, and oversaw corporate strategy and alliances, value and access, communications, policy, advocacy and corporate responsibility.
Before joining Biogen, Guindo began his Merck career in 1990 and spent more than 25 years in finance, sales, commercial and marketing roles of increasing responsibility in the U.S. and globally. He led global marketing for Merck’s HIV portfolio, and also led Merck’s Human Health businesses in Canada, the Netherlands and South Africa. Guindo has been recognized for developing strong talent and forging innovative public-private partnerships and elevating the profile of Merck as a patient-focused company. A graduate of Ecole Centrale de Paris with a degree in engineering, he also holds a Master of Business Administration from New York University’s Stern School of Management.
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).